$EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma$

EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma

On August 25, 2020, a marketing authorization valid through the European Union was issued for belantamab mafodotin monotherapy for the treatment of multiple myeloma (MM) in adult patients who have received at least four prior therapies, whose disease is refractory to at least one proteasome inhibito...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2021-01, Vol.26 (1), p.70-76
Hauptverfasser:	Tzogani, Kyriaki, Penttilä, Karri, Lähteenvuo, Johanna, Lapveteläinen, Tuomo, Lopez Anglada, Lucía, Prieto, Carolina, Garcia‐Ochoa, Blanca, Enzmann, Harald, Gisselbrecht, Christian, Delgado, Julio, Pignatti, Francesco
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - therapeutic use Antimitotic agents Antineoplastic agents Antineoplastic Agents, Immunological - therapeutic use Belantamab mafodotin (Blenrep) Biological products B‐cell maturation antigen Dosage and administration Drug therapy European Medicines Agency Humans Immunoconjugates - therapeutic use Medical research Medicine, Experimental Monoclonal antibodies Multiple myeloma Multiple Myeloma - drug therapy Product information Regulatory Issues: EMA Testing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!